About Excellos
Excellos is a Healthcare company based in San Diego (United States) founded in 2010. Manufacturing services for cell and gene therapies are provided. Excellos has raised $5 million across 2 funding rounds. Its chief executive, as recorded, is David Wellis. Excellos offers products and services including Leukopak, Excellos 360, and Cord Blood Unit. Its focus areas include Biopharma Outsourcing, CDMO, Biologics and Cell and Gene Therapy. Its competitors include Orgenesis and Cognate Bioservices.
Company details
Excellos was founded in 2010 and is headquartered in San Diego, United States. Operations are centered in the biotechnology sector as a contract development and manufacturing organization (CDMO). Services encompass the production of cell and gene therapy products, supporting clinical and commercial-scale manufacturing. Leadership is held by CEO David Wellis, with focus maintained on regulatory-compliant processes for advanced therapies.
- Headquarters San Diego, United States
- SectorsHealthcare
- Email••••••••
- Website excellos.com
- Social LinkedIn X Facebook YouTube
- Total Equity Funding$5M (USD)
in 2 rounds
Products & Services of Excellos
Excellos offers a comprehensive portfolio of products and services, including Leukopak, Excellos 360, and Cord Blood Unit.
Provides isolated cells from peripheral blood for research and therapy.
Offers comprehensive immune cell profiling to assess donor potential.
Supplies cord blood materials for GMP manufacturing and cell therapies.
Apps and channels of Excellos
its YouTube channel Excellos has 6 subscribers and 3 videos.
Videos from Excellos
The most watched videos on Excellos's YouTube channel, Excellos (6 subscribers). Click a video to play it here.
More on Excellos.
Funding Insights of Excellos
Excellos has successfully raised a total of $5M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5M
- Total Rounds 2
- First Round $5M
(Aug 2023)
All 2 funding rounds of Excellos with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | Series A | – | – | – | |
| Aug 2023 | $5M | Series A | – | – | – |
People of Excellos
8 people are tracked at Excellos (2 in leadership, 4 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
David Wellis | CEO | Leadership |
Robert Tressler | Chief Scientific Officer | Leadership |
Terry Kinninger | Board Member | Board & advisors |
Robert Finzi | Board Member | Board & advisors |
Paul Grossman | Board Member | Board & advisors |
Deval Lashkari | Board Member | Board & advisors |
Chase Monckton | Senior Technical Lead | Team |
Joshua Huang | Senior Research Scientist | Team |
Complete people profiles for Excellos
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Excellos
3 dated milestones of Excellos across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Excellos is founded.
- Funding First funding round of $5.0M.
- Funding Latest funding round, Series A,.
Competitors of Excellos
Excellos has 2 listed competitors in our database. They include Orgenesis and Cognate Bioservices.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| orgenesis.com | 2008 | Germantown, United States | 167 | Cell and gene therapies for multiple disorders are developed. | ||
| cognatebioservices.com | 2002 | Hanover, United States | 302 | Development and manufacturing services for cell-based therapies are provided. |
Detailed competitors of Excellos
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Excellos
The website of Excellos (excellos.com) receives about 3.5K visits a month.
- Monthly visits3.5K
▲ 24.3% vs previous month
Websites whose visitors overlap most with Excellos. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| anabios.com | 100% | 3.6K | #4,955,721 | View details | |
abigailsmedicalsupplies.com | abigailsmedicalsupplies.com | 95% | – | ||
| mabplexinc.com | 94% | 1K | #15,283,808 | View details | |
| medizap.co | 90% | #9,808,741 | View details | ||
| curemetrix.com | 88% | 2.7K | #5,895,624 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Excellos
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Excellos (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Excellos
Complete news archive for Excellos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Excellos
Excellos was founded in 2010 and raised its 1st funding round 13 years after it was founded.
Excellos is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
David Wellis is the CEO of Excellos, as recorded in our data.
Excellos is a funded company, having raised a total of $5M across 2 funding rounds to date. The company's 1st funding round was a Series A of $5M, raised on Aug 2023.
Excellos was founded in 2010 and is headquartered in San Diego, United States. Operations are centered in the biotechnology sector as a contract development and manufacturing organization (CDMO). Services encompass the production of cell and gene therapy products, supporting clinical and commercial-scale manufacturing. Leadership is held by CEO David Wellis, with focus maintained on regulatory-compliant processes for advanced therapies.
Excellos's top competitors include Orgenesis and Cognate Bioservices.
Excellos offers Leukopak, Excellos 360, and Cord Blood Unit.